Skip to Content
Søk Menu

Don’t Miss Out on ASH 2023 

Discover the latest in blood and bone marrow disorder research as BestPractice Nordic covers the 65th ASH Annual Meeting. 

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymfom Play the Video 01:08
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video 03:32
Jason Westin

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

/ Jason Westin
ASH23B-celle lymfom Play the Video 2:05
Eva Birgitte Leinøe

Undiagnosed and Unrecognized Patients with a High Bleeding Score

/ Eva Birgitte Leinøe
ASH23 Play the Video 03:43
Pieter Sonneveld

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Pieter Sonneveld
ASH23Myelom Play the Video 05:04

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ BestPractice Nordic
ASH23CLL
Jeff P. Sharman

No increase risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Jeff P. Sharman
ASH23CLL Play the Video 1:45
Gabriel Brisou

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B-Cell Lymphoma

/ Gabriel Brisou
ASH23B-celle lymfom Play the Video 2:39

ASH 2023: FDA Approves Gene Therapies for Sickle Cell Disease

/ BestPractice Nordic
ASH23
Back to top